United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

Aggrecan (PG) Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:PG, ACAN, Aggrecan core protein, Cartilage-specific proteoglycan core protein, CSPCP, Chondroitin sulfate proteoglycan core protein 1, Chondroitin sulfate proteoglycan 1, AGC1, AGCAN, CSPG1, CSPGCP, MSK16, SEDK, SSOAOD
  • Species:Human
Cat. No. Size Price

RIS001R 96 wells (1 kit) $495
PubMed Product Details
Technical Data


Sandwich ELISA, HRP-labelled antibody



Sample Requirements

50 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

10–150 ng/ml

Limit of Detection

0.9 ng/ml


Research topic

Bone and cartilage metabolism, Extracellular matrix


Aggrecan (PG) is the predominant proteoglycan species in articular cartilage. The loss of PG and other matrix components from the cartilage leads to destruction of the tissue, causing complete deterioration of the articular surface. PG and PG fragments released in synovial fluid and serum during this degradation process might serve as markers of the metabolic changes in diseased cartilage.

Summary References (9)

References to Aggrecan

  • Bassleer C, Henrotin Y, Franchimont P. Insulin-Like Growth factor 1 and Glycosaminoglycan-Peptide Complex: Their Effects on Differentiated Human Chondrocytes Cultivated in Clusters. Litera Rheumatologica. 1991;13; 33-44
  • Bassleer C, Henrotin Y, Franchimont P. Effects of a Glycosaminoglycan-Peptide Complex and Interleukin 1 on Differentiated Human Chondrocytes Cultivated in Clusters. Litera Rheumatologica. 1991;13; 21-31
  • Franchimont P, Bassleer C. Effects of hormones and local growth factors on articular chondrocyte metabolism. J Rheumatol Suppl. 1991 Feb;27:68-70
  • Franchimont P, Bassleer C, Henrotin Y. Effects of hormones and drugs on cartilage repair. J Rheumatol Suppl. 1989 Aug;18:5-9
  • Heinegard D, Oldberg A. Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEB J. 1989 Jul;3 (9):2042-51
  • Lohmander LS, Lark MW, Dahlberg L, Walakovits LA, Roos H. Cartilage matrix metabolism in osteoarthritis: markers in synovial fluid, serum, and urine. Clin Biochem. 1992 Jun;25 (3):167-74
  • Poole AR, Ionescu M, Swan A, Dieppe PA. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest. 1994 Jul;94 (1):25-33
  • Saxne T, Heinegard D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum. 1992 Apr;35 (4):385-90
  • Saxne T, Heinegard D, Wollheim FA. Cartilage proteoglycans in synovial fluid and serum in patients with inflammatory joint disease. Relation to systemic treatment. Arthritis Rheum. 1987 Sep;30 (9):972-9
Related Products Docs